Literature DB >> 16258703

Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells.

R J Santen1, E K Lobenhofer, C A Afshari, Y Bao, R X Song.   

Abstract

First line treatment of hormone dependent breast cancer initially causes tumor regression but later results in adaptive changes and tumor re-growth. Responses to second line treatments occur but tumors again begin to progress after a period of 12???18??months. In depth understanding of the adaptive process would allow the identification of targets to abrogate the development of hormonal resistance and prolong the efficacy of endocrine therapy. We have developed a model system to examine adaptive changes in human MCF-7 breast cancer cells. Upon deprivation of estradiol for a prolonged period of time, a maneuver analogous to surgical oophorectomy in pre-menopausal women and use of aromatase inhibitors in post-menopausal patients, tumor cells adapt and become hypersensitive to estradiol. We reasoned that the expression pattern of multiple genes would change in response to estradiol deprivation and that cDNA microarrays would provide an efficient means of assessing these changes. Accordingly, we examined the transcriptional responses to estradiol in long-term estradiol deprived (LTED) MCF-7 cells with a cDNA microarray containing 1901 known genes and ESTs. To assess the changes induced by long-term estradiol deprivation, we compared the effects of estradiol administration in LTED cells with those in MCF-7 cells, which we had previously reported, and confirmed with real time PCR using the parental and LTED cells. Seven genes and one EST were induced by estradiol in LTED but not in wild type MCF-7 cells, whereas ten genes were down-regulated by estradiol only in LTED cells. The expression of seven genes increased concurrently and five decreased in response to estradiol in both cell types. From these observations, we generated testable hypotheses regarding several genes including DKFZP, RAP-1, ribosomal protein S6, and TM4SF1. Based upon the known functions of these genes and the patterns of observed changes, we postulate that divergent regulation of these genes may contribute to the different biologic responses to estrogen in these cell lines. These results provide targets for further mechanistic studies in our experimental system. Our findings indicate that long-term estradiol deprivation causes expression changes in multiple genes and emphasizes the complexity of the process of cellular adaptation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258703     DOI: 10.1007/s10549-005-5776-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  12 in total

Review 1.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

Review 2.  Natural products as aromatase inhibitors.

Authors:  Marcy J Balunas; Bin Su; Robert W Brueggemeier; A Douglas Kinghorn
Journal:  Anticancer Agents Med Chem       Date:  2008-08       Impact factor: 2.505

3.  Novel cancer-targeting SPECT/NIRF dual-modality imaging probe (99m)Tc-PC-1007: synthesis and biological evaluation.

Authors:  Yi Zhang; Li Xiao; Kosta Popovic; Xiuzhen Xie; Mahendra D Chordia; Leland W K Chung; Mark B Williams; Wei Yue; Dongfeng Pan
Journal:  Bioorg Med Chem Lett       Date:  2013-10-01       Impact factor: 2.823

4.  Estrogen stimulation of cell migration involves multiple signaling pathway interactions.

Authors:  Yan Li; Ji-Ping Wang; Richard J Santen; Tae-Hyun Kim; Hoyong Park; Ping Fan; Wei Yue
Journal:  Endocrinology       Date:  2010-09-22       Impact factor: 4.736

5.  Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells.

Authors:  Barbara C Spink; James A Bennett; Brian T Pentecost; Nicole Lostritto; Neal A Englert; Geoffrey K Benn; Angela K Goodenough; Robert J Turesky; David C Spink
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-18       Impact factor: 4.219

6.  Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study.

Authors:  Ross L Prentice; Rowan T Chlebowski; Marcia L Stefanick; Joann E Manson; Robert D Langer; Mary Pettinger; Susan L Hendrix; F Allan Hubbell; Charles Kooperberg; Lewis H Kuller; Dorothy S Lane; Anne McTiernan; Mary Jo O'Sullivan; Jacques E Rossouw; Garnet L Anderson
Journal:  Am J Epidemiol       Date:  2008-04-29       Impact factor: 4.897

7.  Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.

Authors:  Ross L Prentice; Rowan T Chlebowski; Marcia L Stefanick; Joann E Manson; Mary Pettinger; Susan L Hendrix; F Allan Hubbell; Charles Kooperberg; Lewis H Kuller; Dorothy S Lane; Anne McTiernan; Mary Jo O'Sullivan; Jacques E Rossouw; Garnet L Anderson
Journal:  Am J Epidemiol       Date:  2008-03-27       Impact factor: 4.897

Review 8.  The discovery and mechanism of action of letrozole.

Authors:  Ajay S Bhatnagar
Journal:  Breast Cancer Res Treat       Date:  2007-10-03       Impact factor: 4.872

9.  EFEMP1 is repressed by estrogen and inhibits the epithelial-mesenchymal transition via Wnt/β-catenin signaling in endometrial carcinoma.

Authors:  Tingting Yang; Huilin Zhang; Haifeng Qiu; Bilan Li; Jingyun Wang; Guiqiang Du; Chune Ren; Xiaoping Wan
Journal:  Oncotarget       Date:  2016-05-03

10.  Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.

Authors:  Christina Yau; Christopher C Benz
Journal:  Breast Cancer Res       Date:  2008-07-17       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.